Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 9/20 | 0.60 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.60 |
| ▸ | KCNH2 known ✓ | Q12809 | 9/20 | 0.57 |
| ▸ | DRD2 known ✓ | P14416 | 8/20 | 0.57 |
| ▸ | HTR2A known ✓ | P28223 | 8/20 | 0.57 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.53 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.53 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.53 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.53 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.53 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.53 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.53 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.53 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.53 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.53 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.53 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.53 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767939 | 0.98 | HTR1A (0.62) | HTR1AHTR7KCNH2DRD2HTR2A | |
| SCHEMBL6790516 | 0.89 | HTR1A (0.60) | HTR1AHTR7KCNH2DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4891136 | 0.88 | HTR1A (0.59) | HTR1AHTR7KCNH2DRD2HTR2A | |
| SCHEMBL5678980 | 0.86 | HTR1A (0.61) | HTR1AHTR7KCNH2DRD2HTR2A | |
| SCHEMBL9367637 | 0.85 | HTR1A (0.60) | HTR1AHTR7KCNH2DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4895367 | 0.85 | HTR2A (0.57) | HTR1AHTR7KCNH2DRD2HTR2A | |
| SCHEMBL5738492 | 0.85 | HTR1A (0.64) | HTR1AHTR7KCNH2DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4891010 | 0.85 | HTR1A (0.59) | HTR1AHTR7KCNH2DRD2HTR2A | |
| SCHEMBL9367264 | 0.84 | HTR1A (0.58) | HTR1AHTR7KCNH2DRD2HTR2A | |
| SCHEMBL6795599 | 0.84 | HTR1A (0.54) | HTR1AHTR7KCNH2DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1757292-A1 | Method of treating ocd and tic disorders | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1633361-A1 | ANXIETY TREATMENTS WITH ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1633360-A1 | TREATMENT OF PSYCHOTIC AND DEPRESSIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1626722-A1 | METHOD FOR ENHANCING COGNITION USING ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1626723-A1 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| US-20050004137-A1 | Treatment of psychotic and depressive disorders | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| US-6387904-B2 | COMPOUND CONTAINING PIPERAZINE RING | PFIZER INC | 2002-05-14 | — | — | US | disclosed |
| US-20020004504-A1 | METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY | HOWARD HARRY R (US) | 2002-01-10 | — | — | US | disclosed |
| US-6245766-B1 | USING A PIPERAZINE COMPOUND | PFIZER INC | 2001-06-12 | — | — | US | disclosed |
| US-6127373-A | Method of treating tourette's syndrome and obsessive compulsive disorder | PFIZER INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0931547-A1 | Piperazinyl-heterocyclic compounds in the treatment of psychiatric conditions | Pfizer Products Inc. (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0901789-A1 | Method of treating tourette's syndrome | Pfizer Products Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4831031-A | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | PFIZER INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004137-A1 | Treatment of psychotic and depressive disorders | SNCA, NLN, INA | HTR1A 76/4885HTR7 238/4885KCNH2 1513/4885 |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | MC2R, NR3C1, CRH | HTR1A 79/4885HTR7 714/4885KCNH2 1329/4885 |
| US-20020004504-A1 | METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY | ALDH1A2, NDUFB7, PTGS1 | HTR1A 1024/4885HTR7 1380/4885KCNH2 1606/4885 |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | DBH, RAP1A, GABRR1 | HTR1A 50/4885HTR7 290/4885KCNH2 2811/4885 |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | GABBR1, GABRR1, GABBR2 | HTR1A 80/4885HTR7 376/4885KCNH2 2492/4885 |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | NPSR1, AVPR1B, SLC39A3 | HTR1A 126/4885HTR7 610/4885KCNH2 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.